scholarly journals Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes

2016 ◽  
Vol 239 (2) ◽  
pp. 155-158 ◽  
Author(s):  
Yuka Miyoshi ◽  
Osamu Ogawa ◽  
Yu Oyama
Keyword(s):  
Cell Death ◽  
Type 1 Diabetes ◽  
Programmed Cell Death ◽  
Fulminant Type 1 Diabetes ◽  
Programmed Cell Death 1 ◽  
Fulminant Type

Anti-programmed cell death 1 therapy triggering diabetic ketoacidosis and fulminant type 1 diabetes

2016 ◽  
Vol 53 (5) ◽  
pp. 853-856 ◽  
Author(s):  
Sung Hye Kong ◽  
Seo Young Lee ◽  
Ye Seul Yang ◽  
Tae Min Kim ◽  
Soo Heon Kwak
Keyword(s):  
Cell Death ◽  
Type 1 Diabetes ◽  
Programmed Cell Death ◽  
Diabetic Ketoacidosis ◽  
Fulminant Type 1 Diabetes ◽  
Programmed Cell Death 1 ◽  
Fulminant Type

scholarly journals Fulminant type 1 diabetes mellitus with anti‐programmed cell death‐1 therapy

2016 ◽  
Vol 7 (6) ◽  
pp. 915-918 ◽  
Author(s):  
Masahide Okamoto ◽  
Mitsuhiro Okamoto ◽  
Koro Gotoh ◽  
Takayuki Masaki ◽  
Yoshinori Ozeki ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Cell Death ◽  
Type 1 Diabetes ◽  
Programmed Cell Death ◽  
Type 1 Diabetes Mellitus ◽  
Fulminant Type 1 Diabetes ◽  
Programmed Cell Death 1 ◽  
Fulminant Type

scholarly journals Detailed Time Course of Decline in Serum C-Peptide Levels in Anti–Programmed Cell Death-1 Therapy–Induced Fulminant Type 1 Diabetes

Diabetes Care ◽  
2019 ◽  
Vol 42 (3) ◽  
pp. e40-e41 ◽  
Author(s):  
Daigo Saito ◽  
Yoichi Oikawa ◽  
Yuya Yano ◽  
Yuichi Ikegami ◽  
Atsushi Satomura ◽  
...  
Keyword(s):  
Cell Death ◽  
Type 1 Diabetes ◽  
Programmed Cell Death ◽  
Time Course ◽  
Fulminant Type 1 Diabetes ◽  
C Peptide ◽  
Programmed Cell Death 1 ◽  
Fulminant Type

Programmed Cell Death-1 Monoclonal Antibody Therapy and Type 1 Diabetes Mellitus: A Review of the Literature

2019 ◽  
pp. 089719001985092 ◽  
Author(s):  
Kyle A. Farina ◽  
Michael P. Kane
Keyword(s):  
Diabetes Mellitus ◽  
Cell Death ◽  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Programmed Cell Death ◽  
Type 1 Diabetes Mellitus ◽  
Inhibitor Therapy ◽  
Blood Glucose Monitoring ◽  
Programmed Cell Death 1

Two Food and Drug Administration-approved programmed cell death-1 (PD-1) inhibitors, nivolumab (Opdivo®), and pembrolizumab (Keytruda®), are indicated for treatment-resistant malignancies. Inhibition of PD-1 also inhibits T-cell peripheral tolerance, enhancing autoimmunity. Various autoimmune conditions have been reported with the use of these agents, including type 1 diabetes mellitus (T1DM). This article reviews literature regarding the development of T1DM in patients treated with PD-1 inhibitors and identifies strategies for the appropriate identification, monitoring, and follow-up of these patients. Published cases of T1DM related to PD-1 inhibitor therapy were identified using PubMed. Eighty-three identified publications were reviewed, of which 37 publications involving 42 cases of anti-PD-1 therapy-induced T1DM were identified. The average age of patients at presentation was 62 years and 59.5% were male. The mean number of PD-1 inhibitor doses received was 5, with a mean time to presentation of 11 weeks. Initial presentation of diabetic ketoacidosis was reported in 69% of cases, with an average blood glucose of 660 mg/dL and an average HbA1cof 8.7%. The exact mechanism PD-1 inhibitor therapy-induced T1DM is unknown. Blood glucose monitoring is recommended for all patients receiving anti-PD-1 therapy. Further research is needed to delineate the frequency of this adverse effect, as well as to evaluate potential risk factors and ideal management strategies.

scholarly journals Simultaneous development of Graves’ disease and type 1 diabetes during anti‐programmed cell death‐1 therapy: A case report

2020 ◽  
Vol 11 (4) ◽  
pp. 1006-1009 ◽  
Author(s):  
Susumu Kurihara ◽  
Yoichi Oikawa ◽  
Ritsuko Nakajima ◽  
Atsushi Satomura ◽  
Ryuhei Tanaka ◽  
...  
Keyword(s):  
Cell Death ◽  
Type 1 Diabetes ◽  
Case Report ◽  
Programmed Cell Death ◽  
Graves Disease ◽  
Simultaneous Development ◽  
Programmed Cell Death 1

scholarly journals Low programmed cell death-1 (PD-1) expression in peripheral CD4+T cells in Japanese patients with autoimmune type 1 diabetes

2015 ◽  
Vol 180 (3) ◽  
pp. 452-457 ◽  
Author(s):  
R. Fujisawa ◽  
F. Haseda ◽  
C. Tsutsumi ◽  
Y. Hiromine ◽  
S. Noso ◽  
...  
Keyword(s):  
T Cells ◽  
Cell Death ◽  
Type 1 Diabetes ◽  
Programmed Cell Death ◽  
Cd4 T Cells ◽  
Japanese Patients ◽  
Programmed Cell Death 1
Sign in / Sign up

Export Citation Format

Share Document